BIOCON Charts, Analysis and Tips

home > pharma-and-healthcare > pharmaceuticals > biocon

Technical Analysis

Technical Strength: 7.3 / 10
Indicator Analysis Signal (0 - 10) Chart
RSI (?) RSI is 72.4. According to RSI analysis, biocon is overbought. 3.0 BIOCON RSI Chart
MACD (?) MACD: 14.0 and Signal Line: 10.1. According to MACD analysis, biocon is technically strong. 8.0 BIOCON MACD Chart
Simple Moving Average (?) According to simple moving average analysis, biocon is in a strong uptrend. Major support levels are 623.505, 610.159, 473.9622. 10.0 BIOCON Simple Moving Average Chart
Exponential Moving Average (?) According to exponential moving average analysis, biocon is in a strong uptrend. Major support levels are 627.9669, 607.4488, 503.6945. 10.0 BIOCON Exponential Moving Average Chart
Bollinger Bands (?) %b is 1.05. According to bollinger bands, biocon has hit the upper band which is a positive signal. 9.0 BIOCON Bollinger Bands Chart
Fibonacci Retracement (?) According to fibonacci retracement, price is above all levels. Major support is at 626.0827 and 613.675. Resistance level is 666.25. 6.5 BIOCON Fibonacci Retracement Chart
Average True Range (?) ATR: 16.6 NA BIOCON Average True Range Chart
Average Directional Index (?) ADX is 27.6 which means BIOCON is in a trend. NA BIOCON Average Directional Index Chart
Note: Technical Analysis updated at 7PM on every trading day.
End-of-Day Share Price - NSE
April 26, 2018
Open Price 655.0
High Price 666.25
Low Price 654.8
Close Price 663.5
Absolute Change 10.85
Percentage Change 1.66%
Weekly Change 3.74%
Monthly Change 9.93%
Yearly Change 82.2%
52-week high 666.25
52-week low 295.033333333
Corporate Actions
ExDate Purpose
July 20, 2017 AGM/DIV-RE 1 PER SHARE
June 15, 2017 BONUS 2:1
June 22, 2016 ANNUAL GENERAL MEETING
See all Corporate Actions
Volume Chart
Real time prices can be delayed by 20 minutes. Prices are refreshed from our server automatically after 1 minute. If NSE real time price is not available then BSE real time prices are provided. Volume displayed might not be correct..

Fundamental Analysis

Beta (?)0.768
Confidence in Beta5.46%
Market Capital Rs. 13268.0 Cr
Diluted Trailing Twelve Months (TTM) Earnings Per Share (EPS) Rs. 14.5566666667
TTM Price-to-Earnings (P/E) Ratio 45.6
Whenever available, consolidated financial results are used. For details, see here.
Stock Deliverable Quantity and Daily Volatility
Indicator Analysis Signal (0 - Strong Sell, 10 - Strong Buy) Chart
Deliverable Quantity (?) 26 April 2018: Deliverable Quantity:5.68e+05 NA BIOCON Deliverable Quantity Chart
Annualized Daily Volatility (Spot Price) (?) 26 April 2018: Daily Volatility:0.3095 NA BIOCON Annualized Daily Volatility (Spot Price) Chart

Futures & Options Analysis

Indicator Analysis Signal (0 - Strong Sell, 10 - Strong Buy) Chart
PCR (?) 26 April 2018: PCR_OI:0.517 PCR:0.302 NA BIOCON PCR Chart
Option Pain (?) 26 April 2018: Max Pain:640.0 NA BIOCON Option Pain Chart
Premium (?) 26 April 2018 Premium: -1.05 Futures OI:918000.0 NA BIOCON Premium Chart
Option_MAX_OI (?) 26 April 2018: Price:663.5 Put with maximum OI:640.0 Call with maximum OI:680.0 NA BIOCON Option_MAX_OI Chart

Futures - NSE

Expiry Date Close Price Open Interest Number of Trades No of Contracts Underlying Closing Price
April 26, 2018 662.45 918000.0 4718.0 5060.0 663.5
May 31, 2018 666.3 7443000.0 4346.0 4686.0 663.5
June 28, 2018 665.45 102600.0 29.0 29.0 663.5

Announcements

April 12, 2018 BiocUpdatescon Limited has informed the Exchange regarding 'Mylan and Biocon seek to accelerate introduction of Biosimilar adalimumab in EU'.
April 10, 2018 BiocDisc. under Reg.30 of SEBI (SAST) Reg.2011con Limited has submitted to the Exchange a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.
See all Announcements

Board Meetings

Date Meeting Date Purpose
December 22, 2017 January 24, 2018 InteResults/Otherser alia, consider, approve and take on record, the un-audited financial results (both standalone and consolidated) of the Company for the quarter ended December 31, 2017 amongst other routine matters.
September 27, 2017 October 26, 2017 InteResultser alia, consider, approve and take on record, the un-audited financial results (both standalone and consolidated) of the Company for the quarter and half year ended September 30, 2017 amongst other routine matters.
See all Board Meetings

BIOCON is part of...

Index Weightage
NFTYMCAP50 NA
CNXPHARMA NA

Intraday Pivot Points

S3 S2 S1 Pivot R1 R2 R3
Rs. 645.3 Rs. 650.1 Rs. 656.8 Rs. 661.5 Rs. 668.2 Rs. 673 Rs. 679.7